ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae
Science Advances · 07.08.2026 · 12 (32)
DOI: 10.1126/sciadv.aee7981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 07.08.2026. Verfasst von Teerawit Audshasai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Infection Microbiology & Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, The Ro…. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Vaccines, Pneumococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Wellcome, Meningitis Now.
Abstract (Originalsprache)
Existing licensed pneumococcal vaccines, including Prevnar-13 and its higher-valency successors, have played a major role in reducing invasive pneumococcal disease worldwide. However, their effectiveness is increasingly threatened by the rise of multidrug-resistant strains and the shift in circulating serotypes toward those not targeted by current vaccines—a trend known as serotype replacement. These evolving challenges underscore the urgent need for next-generation vaccines with broader, serotype-independent protection—long considered the holy grail of pneumococcal vaccine development. Here, we report the discovery and preclinical evaluation of ZPY-CpG-Ch, a broad-coverage protein-based pneumococcal vaccine formulation. We assessed the protective efficacy and immunogenicity of ZPY-CpG-Ch in translational murine models, using both adult and neonatal mice, and tested various adjuvants, protein combinations, and doses, followed by challenge experiments with both vaccine- and non–vaccine-covered serotypes. Prevnar-13 was included as a benchmark. While Prevnar-13 ® demonstrated robust efficacy, our results show that ZPY-CpG-Ch achieves greater cross-serotype protection. We attribute this enhanced efficacy primarily to T H 17 (T helper 7)–biased immune responses. Together, these findings highlight the promise of genome-guided, protein-based vaccines in overcoming the limitations of current serotype-based approaches and represent a meaningful step toward a truly universal pneumococcal vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Infection Microbiology & Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, The Ronald Ross Building, 8 West Derby St., Liverpool L69 7BE, UK.
- Department of Microbiology, Faculty of Pharmacy, Mahidol University, 447, Thanon Si Ayutthaya, Khwaeng Thung Phaya Thai, Khet Ratchathewi, Bangkok 10400, Thailand.
- SequenceAnalysis.co.uk, Norwich Research Park, Norwich NR4 7UG, UK.
- School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
- Host-Microbe Interactions Dept. at St Jude Children's Research Hospital, Danny Thomas Place, Memphis, TN 38105, USA.
ORCID-Profile: Teerawit Audshasai, Stavros Panagiotou, Lisa Crossman, Rong Xu, Lynn Verheijen, Chrispin Chaguza, Marie O'Brien, Aras Kadioglu
Förderung
- Wellcome Trust
- Wellcome
- Meningitis Now
- Medical Research Council
- UK Medical Research Council
- Liverpool-Mahidol
Zitieren
APA
Audshasai, T., Panagiotou, S., Crossman, L., Xu, R., Verheijen, L., Chaguza, C., O'Brien, M., & Kadioglu, A. (2026). ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae. Science Advances, 12(32). https://doi.org/10.1126/sciadv.aee7981
Vancouver
Audshasai T, Panagiotou S, Crossman L, Xu R, Verheijen L, Chaguza C, et al. ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae. Science Advances. 2026;12(32). doi:10.1126/sciadv.aee7981
BibTeX
@article{Audshasai2026,
author = {Audshasai, Teerawit and Panagiotou, Stavros and Crossman, Lisa and Xu, Rong and Verheijen, Lynn and Chaguza, Chrispin and O'Brien, Marie and Kadioglu, Aras},
title = {ZPY-CpG-Ch, a broad coverage vaccine against Streptococcus pneumoniae},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {32},
doi = {10.1126/sciadv.aee7981}
}
EUVIMED